Central Nervous System Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrollment complete
Mid-Phase III
TNX-102 SL Long COVID
Phase II start — PREVAIL study enrollment complete
Phase II
TNX-601 ER Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids
Phase II start — UPLIFT study enrollment complete
Phase II
TNX-1300 Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation
Mid-Phase II
TNX-1900 Chronic Migraine
Phase II start — PREVENTION study enrollment complete
Phase II
TNX-4300 Depression, Bipolar Disorder, Alzheimer’s disease and Parkinson’s disease
Preclinical
Preclinical
Rare Disease Portfolio
Preclinical
Phase I
Phase II
Phase III
TNX-2900 Prader-Willi Syndrome
Phase II ready – FDA Orphan Drug Designation
Preclinical